Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Pursues Futura Medical's OTC Topical NSAID Under Development

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline's relationship with Futura Medical is on again as the pharmaceutical giant agrees to fund development of Futura's novel topical pain reliever TPR100

You may also be interested in...

GSK Expands Consumer Business With Acquisition Of OTC Cold Sore Products

GlaxoSmithKline further expands its rapidly growing consumer health care business by acquiring exclusive marketing rights to two cold sore treatments in a week, just months after announcing a third deal in the category

Ibuprofen Topicals Draw Unapproved New Drug Warnings

FDA's initiative to remove unapproved new drugs from the market extends to topical ibuprofen products as the agency warns eight firms about lotions containing the common nonprescription ingredient

Under New CEO, Glaxo Will Leverage OTCs In Emerging Markets

GlaxoSmithKline will seed its growth in emerging markets with OTC drugs and other nonprescription products, according to Chris Viehbacher, the firm's North American Pharmaceuticals division president





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts